| Li, Jingao |
NCT06277050: Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 264 | RoW | Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy | 02/29 | 02/30 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
NCT05893810: Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis |
|
|
| Recruiting | 3 | 176 | RoW | Mupirocin Ointment | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, Radiation-induced Oral Mucositis, Bacterial Colonization, Quality of Life | 04/24 | 12/24 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 212 | RoW | PD-1 blocking antibody, JS001, GP, IMRT | Sun Yat-sen University | Recurrent Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial |
|
|
| Recruiting | 3 | 212 | RoW | Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC |
|
|
| Recruiting | 3 | 200 | RoW | PD-1 antibody, Gemcitabine, Cisplatin, IMRT | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 03/26 | 03/26 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 08/26 | 08/29 | | |
NCT05941741: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC |
|
|
| Recruiting | 3 | 380 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy, Induction chemotherapy, Concurrent chemotherapy, Gemcitabine, Cisplatin, Immune checkpoint inhibitor, Cadonilimab, AK104, PD-1/CTLA-4 inhibitor, Low-dose radiotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy | 12/26 | 12/29 | | |
NCT06259721: Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 22 | RoW | Anti-PD1 antibody, nimotuzumab and capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 02/26 | 08/26 | | |
ST-CR01, NCT05755009: High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor |
|
|
| Recruiting | 2 | 33 | RoW | High- and Low-dose radiotherapy | Jiangxi Provincial Cancer Hospital | Metastatic Cancer | 02/24 | 02/25 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 63 | RoW | consolidative radiotherapy, local consolidative radiotherapy | Jiangxi Provincial Cancer Hospital | Oligometastatic Disease | 05/25 | 05/26 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
TQB2618-AK105-Ib-02, NCT05783921: A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 60 | RoW | TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma | 08/24 | 01/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06268600: The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 320 | RoW | Modified neck target volume delineation | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Hypothyroidism | 11/24 | 11/25 | | |
NCT06182657: The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC |
|
|
| Recruiting | N/A | 300 | RoW | | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment | 06/27 | 06/29 | | |
| Li, Jin-gao |
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy | Nanobiotix | Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | 06/26 | 06/27 | | |
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 540 | RoW | PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma | 05/25 | 05/27 | | |
NCT03539250: Dose Constraints for the Temporal Lobes of Intensity-modulated Radiotherapy Treatment Plans for Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | N/A | 350 | NA | IMRT | Jiangxi Provincial Cancer Hospital, Sixth Affiliated Hospital, Sun Yat-sen University | Injury; Temporal Region | 05/20 | 05/25 | | |
| Shuang |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
